Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Rollover Study of Levosimendan in PH-HFpEF
NCT03624010Phase 2Completed
- Sponsor
- Tenax Therapeutics
- Start
- Apr 2019
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levosimendan in pulmonary hypertension (PH), heart failure with preserved ejection fraction (HFpEF), sponsored by Tenax Therapeutics. Started Apr 2019; status: completed.
02
Drugs
levosimendan
03
Conditions
pulmonary hypertension (PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03624010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624010.